Literature DB >> 17964169

Synthesis, nicotinic acetylcholine receptor binding, and pharmacological properties of 3'-(substituted phenyl)deschloroepibatidine analogs.

F Ivy Carroll1, Yasuno Yokota, Wei Ma, Jeffrey R Lee, Lawrence E Brieaddy, Jason P Burgess, Hernán A Navarro, M I Damaj, Billy R Martin.   

Abstract

A series of 3'-(substituted phenyl)deschloroepibatidine analogs (5a-j) were synthesized. The alpha4beta2( *) and alpha7 nicotinic acetylcholine receptor (nAChR) binding properties and functional activity in the tail-flick, hot-plate, locomotor, and body temperature tests in mice of 5a-j were compared to those of the nAChR agonist, nicotine (1), epibatidine (4), and deschloroepibatidine (13), the partial agonist, varenicline (3), and the antagonist 2'-fluoro-3'-(substituted phenyl)deschloroepibatidine analogs (7a-j). Unlike epibatidine and deschloroepibatidine, which are potent agonists in the tail-flick test, 5a-k show no or very low antinociceptive activity in the tail-flick or hot-plate test. However, they are potent antagonists in nicotine-induced antinociception in the tail-flick test, but weaker than the corresponding 2'-fluoro-3'-(substituted phenyl)deschloroepibatidines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17964169      PMCID: PMC2374917          DOI: 10.1016/j.bmc.2007.10.027

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  15 in total

1.  Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2'-fluoro-3'-(substituted phenyl)deschloroepibatidine analogues. Novel nicotinic antagonist.

Authors:  F Ivy Carroll; Roy Ware; Lawrence E Brieaddy; Hernán A Navarro; M I Damaj; Billy R Martin
Journal:  J Med Chem       Date:  2004-08-26       Impact factor: 7.446

2.  Synthesis and pharmacological characterization of exo-2-(2'-chloro-5-pyridinyl)-7-(endo and exo)-aminobicyclo[2.2.1]heptanes as novel epibatidine analogues.

Authors:  F Ivy Carroll; Lawrence E Brieaddy; Hernán A Navarro; M I Damaj; Billy R Martin
Journal:  J Med Chem       Date:  2005-11-17       Impact factor: 7.446

3.  Varenicline.

Authors:  Raymond Niaura; Carole Jones; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2006-07       Impact factor: 84.694

4.  Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3'-substituted deschloroepibatidine analogues. Novel nicotinic antagonists.

Authors:  F Ivy Carroll; Wei Ma; Yasuno Yokota; Jeffrey R Lee; Lawrence E Brieaddy; Hernán A Navarro; M I Damaj; Billy R Martin
Journal:  J Med Chem       Date:  2005-02-24       Impact factor: 7.446

Review 5.  Varenicline: a review of its use as an aid to smoking cessation therapy.

Authors:  Gillian M Keating; M Asif A Siddiqui
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2'-substituted 5'-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Epibatidine analogues.

Authors:  F I Carroll; F Liang; H A Navarro; L E Brieaddy; P Abraham; M I Damaj; B R Martin
Journal:  J Med Chem       Date:  2001-06-21       Impact factor: 7.446

7.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

8.  Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2'-substituted-3'-phenyl-5'-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Novel nicotinic antagonist.

Authors:  F I Carroll; J R Lee; H A Navarro; L E Brieaddy; P Abraham; M I Damaj; B R Martin
Journal:  J Med Chem       Date:  2001-11-22       Impact factor: 7.446

9.  Estimates of global mortality attributable to smoking in 2000.

Authors:  Majid Ezzati; Alan D Lopez
Journal:  Lancet       Date:  2003-09-13       Impact factor: 79.321

10.  Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2',3'-disubstituted 5'-pyridinyl)-7-azabicyclo[2.2.1]heptanes: epibatidine analogues.

Authors:  F Ivy Carroll; Jeffrey R Lee; Hernán A Navarro; Wei Ma; Lawrence E Brieaddy; Philip Abraham; M I Damaj; Billy R Martin
Journal:  J Med Chem       Date:  2002-10-10       Impact factor: 7.446

View more
  10 in total

1.  Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration.

Authors:  Olivier George; Allison Lloyd; F Ivy Carroll; M Imad Damaj; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

2.  The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.

Authors:  Colin S Cunningham; Lance R McMahon
Journal:  Eur J Pharmacol       Date:  2010-12-21       Impact factor: 4.432

3.  Synthesis and nicotinic acetylcholine receptor in vitro and in vivo pharmacological properties of 2'-fluoro-3'-(substituted phenyl)deschloroepibatidine analogues of 2'-fluoro-3'-(4-nitrophenyl)deschloroepibatidine.

Authors:  Pauline Ondachi; Ana Castro; Charles W Luetje; M Imad Damaj; S Wayne Mascarella; Hernán A Navarro; F Ivy Carroll
Journal:  J Med Chem       Date:  2012-07-11       Impact factor: 7.446

4.  Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.

Authors:  Nick C Ortiz; Heidi C O'Neill; Michael J Marks; Sharon R Grady
Journal:  Nicotine Tob Res       Date:  2012-01-12       Impact factor: 4.244

5.  EPIBATIDINE ANALOGS SYNTHESIZED FOR CHARACTERIZATION OF NICOTINIC PHARMACOPHORES-A REVIEW.

Authors:  F Ivy Carroll
Journal:  Heterocycles       Date:  2009       Impact factor: 0.831

6.  The antinociceptive effects of nicotinic partial agonists varenicline and sazetidine-A in murine acute and tonic pain models.

Authors:  Shakir D AlSharari; F Ivy Carroll; J Michael McIntosh; M Imad Damaj
Journal:  J Pharmacol Exp Ther       Date:  2012-06-07       Impact factor: 4.030

7.  Synthesis, nicotinic acetylcholine receptor binding, in vitro and in vivo pharmacology properties of 3'-(substituted pyridinyl)-deschloroepibatidine analogs.

Authors:  Pauline W Ondachi; Zhuo Ye; Ana H Castro; Charles W Luetje; M Imad Damaj; S Wayne Mascarella; Hernán A Navarro; F Ivy Carroll
Journal:  Bioorg Med Chem       Date:  2015-07-17       Impact factor: 3.641

8.  Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3'-(substituted phenyl)epibatidine analogues. Nicotinic partial agonists.

Authors:  F Ivy Carroll; Wei Ma; Liu Deng; Hernán A Navarro; M Imad Damaj; Billy R Martin
Journal:  J Nat Prod       Date:  2010-03-26       Impact factor: 4.050

9.  Preclinical Pharmacology, Efficacy and Safety of Varenicline in Smoking Cessation and Clinical Utility in High Risk Patients.

Authors:  Zheng-Xiong Xi
Journal:  Drug Healthc Patient Saf       Date:  2010-04-01

10.  Competitive docking model for prediction of the human nicotinic acetylcholine receptor α7 binding of tobacco constituents.

Authors:  Hui Wen Ng; Carmine Leggett; Sugunadevi Sakkiah; Bohu Pan; Hao Ye; Leihong Wu; Chandrabose Selvaraj; Weida Tong; Huixiao Hong
Journal:  Oncotarget       Date:  2018-02-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.